Benzinga | Oct 6, 2021 08:22AM EDT

BDX's Rotarex Atherectomy System Wins FDA Indication Expansion Approval

* Becton, Dickinson And Co (NYSE:BDX) has received FDA 510(k) clearance for expanded indications for the Rotarex Atherectomy System.

* Related: BDX Stock Plunges Despite Q3 Earnings Topping Estimates On Recovery In Elective Volumes; Raised FY21 Guidance.

* The Rotarex Atherectomy System is a rotational excisional device built to remove and aspirate varying lesion morphologies, including plaque and thrombus in the peripheral arteries.

* The Rotarex System, already cleared for use in native arterial vessels, now has the expanded indications to treat within peripheral arteries fitted with stents, stent-grafts, and native or artificial bypasses.

* Related content: Benzinga's Full FDA Calendar.

* Price Action: BDX stock closed 1.08% higher at $243.06 on Tuesday.